The eligibility of patients for [177Lu]Lu-PSMA-617 treatment was based on the outcome of two ways: analyzing the tumor tissue PSMA expression by immunohistochemistry and on the tumor uptake above the liver SUVmax on [68Ga]Ga-PSMA-11 PET-CT. Here, FOLH1 is linked to neoplasm.